KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Income (2016 - 2025)

Historic Net Income for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q4 2025 value amounting to $1.2 billion.

  • Vertex Pharmaceuticals' Net Income rose 3046.0% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 billion, marking a year-over-year increase of 83808.81%. This contributed to the annual value of $4.0 billion for FY2025, which is 83808.81% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Net Income stood at $1.2 billion for Q4 2025, which was up 3046.0% from $1.1 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Net Income high stood at $1.2 billion for Q4 2025, and its period low was -$3.6 billion during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' Net Income averaged around $635.1 million, with its median value being $882.4 million (2021).
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Net Income surged by 110970.15% in 2022, and later plummeted by 49244.29% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Income (Quarter) stood at $770.1 million in 2021, then rose by 6.34% to $818.9 million in 2022, then rose by 18.31% to $968.8 million in 2023, then fell by 5.76% to $913.0 million in 2024, then soared by 30.46% to $1.2 billion in 2025.
  • Its last three reported values are $1.2 billion in Q4 2025, $1.1 billion for Q3 2025, and $1.0 billion during Q2 2025.